Investor Presentation September 30, 2025 CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be reli ...

Core Insights - The Canadian cannabis market is crucial for the global marijuana industry, with U.S. legalization efforts expected to drive growth and cross-border opportunities [1][15] - Leading Canadian cannabis stocks are gaining investor attention due to improving financials and international expansion, particularly Cronos Group, Aurora Cannabis, and OrganiGram [2][15] Industry Overview - The U.S. cannabis industry is projected to exceed $56 billion by 2030, driven by expanding state programs and rising consumer acceptance [1] - Discussions around federal reclassification and potential legalization are creating optimism in both Canadian and American markets [1] Company Summaries Cronos Group - Cronos Group operates several global brands and has an indirect presence in the U.S. through a partnership with PharmaCann, which operates over twenty dispensaries [3][6] - The company exited the U.S. CBD market in 2023 to focus on higher-margin international products, improving operational efficiency and long-term growth potential [3][6] - Financially, Cronos reported steady revenue growth in 2024, reduced operating losses, and a strong balance sheet supported by Altria Group [6][8] Aurora Cannabis - Aurora Cannabis is a leader in the global cannabis sector with large-scale cultivation facilities and a focus on medical and recreational products [8][10] - The company has positioned itself for U.S. market entry upon federal legalization and has a strong international presence in Europe, Australia, and South America [8][10] - Aurora achieved revenue growth in 2025, positive gross margins, and a small net income after years of losses, reflecting a notable financial recovery [10] OrganiGram Holdings - OrganiGram is recognized for its agility and rapid growth, enhancing its international presence through partnerships and the recent acquisition of Motif Labs [11][13] - The company achieved record quarterly revenues and positive adjusted EBITDA in 2025, driven by strong sales of premium products and improved production efficiency [13] - OrganiGram's focus on higher-margin segments and global export potential continues to attract investor interest, with positive trends in its financial performance [13][14]

Financial Data and Key Metrics Changes - The company reported record full year net revenue of $920 million, a 1.3% increase compared to the prior year [14] - Q4 2024 net revenue reached a record $257.7 million, a 3.7% increase year-over-year [11] - Gross profit for the full year was $240 million, reflecting a 26% growth compared to the prior year [14] - Q4 gross profit was $68.8 million, a 20% increase year-over-year, resulting in a gross margin of 26.7% [12] - Free cash flow for the full year was positive at $8.9 million, representing a $70 million improvement compared to 2023 [16] Business Line Data and Key Metrics Changes - The cannabis segment achieved a combined business growth of 16.5%, driven by the Indiva acquisition [11] - Liquor segment revenue was impacted by a market slowdown, with a decline of 3.4% in Q4 compared to the same period last year [21] - Cannabis retail reported Q4 net revenue of $83.2 million, a 10.7% increase year-over-year, and full year revenue of $311.7 million, a 7.5% growth [22][23] - Cannabis operations segment net revenue reached $37.1 million in Q4, with a 42% growth compared to the prior year [25] Market Data and Key Metrics Changes - The liquor retail segment faced a decline in same-store sales, with expectations for flat revenue in 2025 [42] - The cannabis market is experiencing strong momentum, with the company gaining market share and expanding distribution points [28][30] Company Strategy and Development Direction - The company is focused on long-term growth through strategic initiatives, including the acquisition of Endiva, positioning it as the largest manufacturer of infused edibles in Canada [7][29] - The company plans to continue building its infrastructure in Canada while exploring opportunities in core US markets [49] - The company aims to achieve $100 million in annualized free cash flow within the next three years [38] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in liquor sales across North America, with expectations for a flat revenue outlook in 2025 [42] - The company remains optimistic about the long-term potential of its US investments despite current operational challenges [48] - Management emphasized the importance of operational improvements and cost efficiencies to drive future profitability [32] Other Important Information - The company ended the year with $218 million in unrestricted cash and zero outstanding debt, providing a competitive advantage for capital allocation [8] - The company announced its application for listing on the Canadian Stock Exchange, which will provide additional flexibility for growth [7] Q&A Session Summary Question: Outlook for liquor retail segment given weak same-store sales - Management acknowledged a slowdown in liquor sales across North America and anticipates flat revenue for 2025, with a long-term growth rate of 1-1.5% expected [42][44] Question: Performance of US investments and potential need for additional capital - Management indicated that while there are operational challenges, they see opportunities for improvement and are focused on capital deployment in Canada and core US markets [48][49] Question: Rationale behind CSE listing application - Management stated that the listing creates optionality for future growth, but emphasized that they are not currently positioned to engage in plant-touching activities [53]